Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical

NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.

NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down

NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.

NuVasive (NUVA) Misses Q3 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -40.74% and -7.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Reports Next Week: What Awaits?

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line

According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.

NuVasive (NUVA) Expands Training Opportunities With New Center

NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.

Debanjana Dey headshot

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

NuVasive (NUVA) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NuVasive (NUVA) Down 6.1% Since Last Earnings Report: Can It Rebound?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up

NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.

NuVasive (NUVA) Beats Q2 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 39.54% and 3.03%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery

The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.

NuVasive (NUVA) Earnings Expected to Grow: Should You Buy?

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

Why Is NuVasive (NUVA) Down 5.2% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up

NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.

NuVasive (NUVA) Beats Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 12.12% and 3.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Enters Overbought Territory

NuVasive (NUVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod

NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.

Why Is NuVasive (NUVA) Up 15.4% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?

NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.

NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies

NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.

NuVasive (NUVA) Enters Overbought Territory

NuVasive (NUVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company